Phenotype and prognostic factors in geriatric and non-geriatric patients with transthyretin cardiomyopathy.
ATTR‐CM
Genetic testing
Geriatric
Observational
Prognostic factors
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
revised:
07
12
2023
received:
21
06
2023
accepted:
21
03
2024
medline:
18
7
2024
pubmed:
18
7
2024
entrez:
18
7
2024
Statut:
aheadofprint
Résumé
Transthyretin cardiac amyloidosis (ATTR-CM) may be an underestimated cause of heart failure among geriatric patients and represent a unique phenotype and prognostic profile. This retrospective, observational, cohort study characterizes cardiac and extracardiac disorders at diagnosis and assesses prognosis among ATTR-CM patients based on age (geriatric vs. non-geriatric) and amyloidosis subtype (wild type, ATTRwt and hereditary, ATTRv). In total, 943 patients with ATTR-CM were included, of which 306 had ATTRv and 637 had ATTRwt. Among these, 331 (35.1%) were non-geriatric (<75 years), and 612 (64.9%) were geriatric (≥75 years). The population exhibited conduction abnormalities, atrial fibrillation and ischaemic heart disease that progressively deteriorated with age. Among ATTRwt patients, peripheral neuropathy, neurovegetative symptoms, and hearing loss were present across all age groups, but reports of carpal tunnel symptoms or surgery decreased with age. Conversely, among ATTRv patients, reports of extracardiac symptoms increased with age and Val122ILe mutation was highly prevalent among geriatric patients. The 3-year survival was higher among non-geriatric ATTR-CM patients (76%) than geriatric patients (55%) and predictors of 3-year mortality differed. Notably, predictors identified among geriatric patients were alkaline phosphatase (ALP) (HR = 1.004, 95% CI: [0.001-1.100)], troponin T hs (HR = 1.005, 95% CI: [1.001-1.120)] and tricuspid insufficiency (HR = 1.194, 95% CI: [1.02-1.230)]. Whereas, among non-geriatric patients, NT-proBNP (HR = 1.002, 95% CI: [1.02-1.04], global longitudinal strain (HR = 0.95, 95% CI: [0.922-0.989], and glomerular filtration rate (HR = 0.984, 95% CI: [0.968-1.00) were identified. We propose a 3-stage prognostic staging system combining troponin T hs (≥44 ng/L) and ALP levels (≥119 UI/L). In the geriatric population, this model discriminated survival more precisely than the National Amyloidosis Centre staging, particularly for classifying between stage 1 (82%), stage 2 (50%) and stage 3 (32%) for ATTRv and ATTRwt. These diagnostic and prognostic indicators, along with ATTR subtype, highlight the distinct characteristics of this important, geriatric ATTR-CM patient group. Recognizing these mortality markers can be valuable for geriatricians to improve the prognostic quality management of geriatric patients with ATTR-CM.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Damy T, Kristen AV, Suhr OB, Maurer MS, Planté‐Bordeneuve V, Yu CR, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS). Eur Heart J 2019;43:391‐400. doi:10.1093/eurheartj/ehz173
Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med 2017;281:337‐347. doi:10.1111/joim.12585
Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 2021;268:2109‐2122. doi:10.1007/s00415‐019‐09688‐0
Coelho T, Maurer MS, Suhr OB. THAOS ‐ The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild‐type transthyretin amyloidosis. Curr Med Res Opin 2013;29:63‐76. doi:10.1185/03007995.2012.754348
Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild‐type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016;68:1014‐1020. doi:10.1016/j.jacc.2016.06.033
Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail 2019;12:e006075. doi:10.1161/circheartfailure.119.006075
Benson MD, Dasgupta NR, Rissing SM, Smith J, Feigenbaum H. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid 2017;24:219‐225. doi:10.1080/13506129.2017.1374946
González‐López E, Gagliardi C, Dominguez F, Quarta CC, de Haro‐del Moral FJ, Milandri A, et al. Clinical characteristics of wild‐type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J 2017;38:1895‐1904. doi:10.1093/eurheartj/ehx043
Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203‐1212. doi:10.1161/circulationaha.108.843334
González‐López E, Gallego‐Delgado M, Guzzo‐Merello G, de Haro‐del Moral FJ, Cobo‐Marcos M, Robles C, et al. Wild‐type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585‐2594. doi:10.1093/eurheartj/ehv338
Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: a population‐based autopsy study. Ann Med 2008;40:232‐239. doi:10.1080/07853890701842988
Porcari A, Bussani R, Merlo M, Varrà GG, Pagura L, Rozze D, et al. Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post‐mortem examination. Front Cardiovasc Med 2021;8:749523. doi:10.3389/fcvm.2021.749523
Lane T, Fontana M, Martinez‐Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 2019;140:16‐26. doi:10.1161/CIRCULATIONAHA.118.038169
Andres TM, McGrane T, McEvoy MD, Allen BFS. Geriatric pharmacology: an update. Anesthesiol Clin 2019;37:475‐492. doi:10.1016/j.anclin.2019.04.007
Kharoubi M, Bézard M, Broussier A, Galat A, Gounot R, Poullot E, et al. Amylo‐AFFECT‐QOL, a self‐reported questionnaire to assess health‐related quality of life and to determine the prognosis in cardiac amyloidosis. Front Cardiovas Med 2023;10:10. doi:10.3389/fcvm.2023.1124660
Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez‐Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39:2799‐2806. doi:10.1093/eurheartj/ehx589
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington‐Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007‐1016. doi:10.1056/NEJMoa1805689
Adams D, Gonzalez‐Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018;379:11‐21. doi:10.1056/NEJMoa1716153
Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid 2020;27:52‐58. doi:10.1080/13506129.2019.1685487
Garcia‐Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554‐1568. doi:10.1093/eurheartj/ehab072
Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta‐analysis of randomised controlled trials. Lancet 2020;396:1637‐1643. doi:10.1016/S0140‐6736(20)32332‐1
Tromp J, Paniagua SMA, Lau ES, Allen NB, Blaha MJ, Gansevoort RT, et al. Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ 2021;372:n461. doi:10.1136/bmj.n461
Zoghbi WA, Adams D, Bonow RO, Enriquez‐Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30:303‐371. doi:10.1016/j.echo.2017.01.007
Davies DR, Redfield MM, Scott CG, Minamisawa M, Grogan M, Dispenzieri A, et al. A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol 2022;7:1036‐1044. doi:10.1001/jamacardio.2022.1781
Brunjes DL, Castano A, Clemons A, Rubin J, Maurer MS. Transthyretin cardiac amyloidosis in older Americans. J Card Fail 2016;22:996‐1003. doi:10.1016/j.cardfail.2016.10.008
Sanchis K, Cariou E, Colombat M, Ribes D, Huart A, Cintas P, et al. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality. Amyloid 2019;26:128‐138. doi:10.1080/13506129.2019.1620724
Rehorn MR, Loungani RS, Black‐Maier E, Coniglio AC, Karra R, Pokorney SD, et al. Cardiac implantable electronic devices: a window into the evolution of conduction disease in cardiac amyloidosis. JACC Clin Electrophysiol 2020;6:1144‐1154. doi:10.1016/j.jacep.2020.04.020
Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies. Eur J Heart Fail 2022;24:2342‐2351. doi:10.1002/ejhf.2532
Broussier A, David JP, Kharoubi M, Oghina S, Segaux L, Teiger E, et al. Frailty in wild‐type transthyretin cardiac amyloidosis: the tip of the iceberg. J Clin Med 2021;10:10. doi:10.3390/jcm10153415
Béquignon E, Guellich A, Bartier S, Raynal M, Prulière‐Escabasse V, Canouï‐Poitrine F, et al. How your ears can tell what is hidden in your heart: wild‐type transthyretin amyloidosis as potential cause of sensorineural hearing loss in elderly‐AmyloDEAFNESS pilot study. Amyloid 2017;24:96‐100. doi:10.1080/13506129.2017.1330744
Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, et al. Prevalence, characteristics and outcomes of older patients with hereditary versus wild‐type transthyretin amyloid cardiomyopathy. Eur J Heart Fail 2023;25:515‐524. doi:10.1002/ejhf.2776
Chacko L, Karia N, Venneri L, Bandera F, Passo BD, Buonamici L, et al. Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. Eur J Heart Fail 2022;24:1700‐1712. doi:10.1002/ejhf.2606
Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, Koutsis G, Toskas P, Lazaros G, et al. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis. Eur J Heart Fail 2022;24:1677‐1696. doi:10.1002/ejhf.2589
Fagot J, Lavie‐Badie Y, Blanchard V, Fournier P, Galinier M, Carrié D, et al. Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis. ESC Heart Fail 2021;8:438‐446. doi:10.1002/ehf2.13093
Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879‐2887. doi:10.1093/eurheartj/ehx350
Fabbri G, Serenelli M, Cantone A, Sanguettoli F, Rapezzi C. Transthyretin amyloidosis in aortic stenosis: clinical and therapeutic implications. Eur Heart J Suppl 2021;23:E128‐e132. doi:10.1093/eurheartj/suab107
Boldrini M, Cappelli F, Chacko L, Restrepo‐Cordoba MA, Lopez‐Sainz A, Giannoni A, et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2020;13:909‐920. doi:10.1016/j.jcmg.2019.10.011
Conceição I, Damy T, Romero M, Galán L, Attarian S, Luigetti M, et al. Early diagnosis of ATTR amyloidosis through targeted follow‐up of identified carriers of TTR gene mutations. Amyloid 2019;26:3‐9. doi:10.1080/13506129.2018.1556156
Barker N, Judge DP. Counseling family members and monitoring for evidence of disease in asymptomatic carriers of amyloid transthyretin cardiac amyloidosis. Am J Cardiol 2022;185:S43‐s50. doi:10.1016/j.amjcard.2022.09.011
Buxbaum JN, Tagoe CE. The genetics of the amyloidoses. Annu Rev Med 2000;51:543‐569. doi:10.1146/annurev.med.51.1.543
Maestro‐Benedicto A, Vela P, de Frutos F, Mora N, Pomares A, Gonzalez‐Vioque E, et al. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy. Eur J Heart Fail 2022;24:2367‐2373. doi:10.1002/ejhf.2658